TSTickerStarGet alerts

MEDS 10-Q filed 2026-11-13 | Key takeaways

MEDS filed its 10-Q; the most relevant disclosure change is expanded Business combinations: Completed Helomics Corporation acquisition on September 11, 2026 for $1.9M (636,328 shares at $0.90/share plus $1.36M convertible note), expanding into precision oncology and laboratory services. Acquired net assets of $1.9M including goodwill of $1.6M.

Share this story

Key takeaways

  • Nine-month 2026 revenues of $6.0M declined 72% year-over-year from $21.7M, reflecting significant decline in Wellgistics distribution revenue due to liquidity constraints.

  • Helomics Corporation acquired September 11, 2026 for $1.9M (stock and convertible note), expanding into precision oncology laboratory services.

  • No single customer exceeded 10% of accounts receivable as of September 30, 2026, down from two customers representing 25% and 18% as of December 31, 2025.

  • Cash declined to $476K from $2.5M at June 30, 2026; working capital deficit of $31.3M with $23.7M of debt due within twelve months raises substantial going concern doubt.

  • Name changed from Wellgistics Health, Inc. to DataMeds AI, Inc. effective July 22, 2026; subsidiary rebranded to Corexa Health, Corexa Pharmacy, and Corexa Tech & Hub.

  • Nasdaq compliance regained for minimum bid price ($1.00) and stockholders' equity ($2.5M) requirements following reverse stock split and equity transactions.

Key metrics

Net revenues - Q3Three months ended September 30, 2026
$2,668,980-11.4% from $3,012,904
Net revenues - YTDNine months ended September 30, 2026
$6,008,403-72.3% from $21,667,212
Net income - Q3Three months ended September 30, 2026
$10,535,560from $(34,318,204) loss
Net loss - YTDNine months ended September 30, 2026
$(15,570,262)from $(73,421,571) loss
Diluted EPS - Q3Three months ended September 30, 2026
$2.72from $(23.07)
Diluted EPS - YTDNine months ended September 30, 2026
$(5.89)from $(58.78)
Cash and cash equivalentsSeptember 30, 2026
$476,598
Working capital deficitSeptember 30, 2026
$31,329,749

Disclosure changes

  • Business combinations

    Completed Helomics Corporation acquisition on September 11, 2026 for $1.9M (636,328 shares at $0.90/share plus $1.36M convertible note), expanding into precision oncology and laboratory services. Acquired net assets of $1.9M including goodwill of $1.6M.

    First acquisition contributing to new service line; Helomics reported no revenue and $41K loss post-acquisition.
  • Asset acquisitions

    Healthstar Technologies LLC (51% owned) acquired KareHub platform intellectual property for $2.0M (30,000 shares at closing plus $1.89M variable share obligation), recognizing $3.9M of intellectual property and $1.9M non-controlling interest.

    New technology platform acquisition through 51%-owned subsidiary; 7-year useful life amortization.
  • Debt extinguishments

    September 2026 settlement with Wellgistics sellers extinguished $17.5M principal and $1.7M accrued interest for $450K cash and repurchase of 364,099 shares, resulting in $19.1M gain on debt extinguishment.

    Largest single item driving Q3 net income; eliminates $17.5M of long-term debt.
  • Going concern

    Management concluded substantial doubt exists about the company's ability to continue as a going concern for twelve months following issuance, with $23.7M of debt due within twelve months including $20.3M New Notes maturing May 27, 2027, and cash of only $476K.

    Liquidity position deteriorated significantly despite debt extinguishment; debt quantum increased due to May 2026 refinancing.
  • Subsidiary restructuring

    Company name changed from Wellgistics Health, Inc. to DataMeds AI, Inc. effective July 22, 2026; subsidiaries renamed to Corexa Health, LLC, Corexa Pharmacy, LLC, and Corexa Tech & Hub, LLC on August 10, 2026.

    Corporate rebranding reflects strategic shift toward AI and technology platforms.
  • Non-controlling interest

    First presentation of non-controlling interest of $1.9M in condensed consolidated balance sheets, representing Kare Hub's 49% membership interest in Healthstar Technologies, LLC.

    New minority interest from Healthstar asset acquisition; net loss attributed to NCI was $54K.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow MEDS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert